Inebilizumab reduces neuromyelitis optica spectrum disorder risk independent of FCGR3A polymorphism

被引：5

作者：

Kim, Ho Jin ^{[1
]}

Aktas, Orhan ^{[2
]}

Patterson, Kristina R. ^{[3
]}

Korff, Schaun ^{[3
]}

Kunchok, Amy ^{[4
]}

Bennett, Jeffrey L. ^{[5
,6
]}

Weinshenker, Brian G. ^{[7
]}

Paul, Friedemann ^{[8
,9
,10
,11
]}

Hartung, Hans-Peter ^{[2
,12
,13
,14
]}

Cimbora, Daniel ^{[3
]}

Smith, Michael A. ^{[3
]}

Mittereder, Nanette ^{[3
]}

Rees, William A. ^{[3
]}

She, Dewei ^{[3
]}

Cree, Bruce A. C. ^{[15
]}

机构：

[1] Natl Canc Ctr, Res Inst & Hosp, Dept Neurol, Goyang, South Korea

[2] Heinrich Heine Univ Dusseldorf, Med Fac, Dusseldorf, Germany

[3] Horizon Therapeut, Deerfield, IL USA

[4] Cleveland Clin, Mellen Ctr Multiple Sclerosis, Dept Neurol, Cleveland, OH USA

[5] Univ Colorado, Sch Med, Dept Neurol, Program Neurosci, Anschutz Med Campus, Aurora, CO USA

[6] Univ Colorado, Dept Neurol, Program Immunol, Sch Med, Anschutz Med Campus, Aurora, CO USA

[7] Univ Virginia, Dept Neurol, Charlottesville, VA USA

[8] Max Delbruck Ctr Mol Med, Expt & Clin Res Ctr, Berlin, Germany

[9] Charite Univ Med Berlin, Berlin, Germany

[10] Free Univ Berlin, Berlin, Germany

[11] Humboldt Univ, Berlin, Germany

[12] Univ Sydney, Brain & Mind Ctr, Sydney, NSW, Australia

[13] Med Univ Vienna, Dept Neurol, Vienna, Austria

[14] Palacky Univ Olomouc, Dept Neurol, Olomouc, Czech Republic

[15] Univ Calif San Francisco, UCSF Weill Inst Neurosci, Dept Neurol, San Francisco, CA 94143 USA

来源：

ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY | 2023年 / 10卷 / 12期

关键词：

FC-GAMMA-RIIIA; TREATMENT OUTCOMES; RITUXIMAB; ANTIBODY; BINDING; DESIGN;

D O I：

10.1002/acn3.51911

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

Inebilizumab, a humanized, glycoengineered, IgG1 monoclonal antibody that depletes CD19+ B-cells, is approved to treat aquaporin 4 (AQP4) IgG-seropositive neuromyelitis optica spectrum disorder (NMOSD). Inebilizumab is afucosylated and engineered for enhanced affinity to Fc receptor III-A (FCGR3A) receptors on natural killer cells to maximize antibody-dependent cellular cytotoxicity. Previously, the F allele polymorphism at amino acid 158 of the FCGR3A gene (F158) was shown to decrease IgG-binding affinity and reduce rituximab (anti-CD20) efficacy for NMOSD attack prevention. In contrast, our current findings from inebilizumab-treated NMOSD patients indicate similar clinical outcomes between those with F158 and V158 allele genotypes.

引用

页码：2413 / 2420

页数：8

共 39 条

[1] Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study [J].

Agius, Mark A. ;

Klodowska-Duda, Gabriela ;

Maciejowski, Maciej ;

Potemkowski, Andrzej ;

Li, Jing ;

Patra, Kaushik ;

Wesley, Jacob ;

Madani, Soraya ;

Barron, Gerard ;

Katz, Eliezer ;

Flor, Armando .

MULTIPLE SCLEROSIS JOURNAL, 2019, 25 (02) :235-245

[2]

[Anonymous], 2021, T B LYMPH DIFF PROF

[3] Neuromyelitis optica spectrum disorder Patient experience and quality of life [J].

Beekman, Janine ;

Keisler, Aysha ;

Pedraza, Omar ;

Haramura, Masayuki ;

Gianella-Borradori, Athos ;

Katz, Eliezer ;

Ratchford, John N. ;

Barron, Gerard ;

Cook, Lawrence J. ;

Behne, Jacinta M. ;

Blaschke, Terrence F. ;

Smith, Terry J. ;

Yeaman, Michael R. .

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2019, 6 (04)

[4] Association between B-cell depletion and attack risk in neuromyelitis optica spectrum disorder: An exploratory analysis from N-MOmentum, a double-blind, randomised, placebo-controlled, multicentre phase 2/3 trial [J].

Bennett, Jeffrey L. ;

Aktas, Orhan ;

Rees, William A. ;

Smith, Michael A. ;

Gunsior, Michele ;

Yan, Li ;

She, Dewei ;

Cimbora, Daniel ;

Pittock, Sean J. ;

Weinshenker, Brian G. ;

Paul, Friedemann ;

Marignier, Romain ;

Wingerchuk, Dean ;

Cutter, Gary ;

Green, Ari ;

Hartung, Hans-Peter ;

Kim, Ho Jin ;

Fujihara, Kazuo ;

Levy, Michael ;

Katz, Eliezer ;

Cree, Bruce A. C. ;

N-MOmentum Study Investigator .

EBIOMEDICINE, 2022, 86

[5] B lymphocytes in neuromyelitis optica [J].

Bennett, Jeffrey L. ;

O'Connor, Kevin C. ;

Bar-Or, Amit ;

Zamvil, Scott S. ;

Hemmer, Bernhard ;

Tedder, Thomas F. ;

von Buedingen, H. -Christian ;

Stuve, Olaf ;

Yeaman, Michael R. ;

Smith, Terry J. ;

Stadelmann, Christine .

NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2015, 2 (03) :e104

[6] Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].

Cartron, G ;

Dacheux, L ;

Salles, G ;

Solal-Celigny, P ;

Bardos, P ;

Colombat, P ;

Watier, H .

BLOOD, 2002, 99 (03) :754-758

[7] Inebilizumab, a B Cell-Depleting Anti-CD19 Antibody for the Treatment of Autoimmune Neurological Diseases: Insights from Preclinical Studies [J].

Chen, Ding ;

Gallagher, Sandra ;

Monson, Nancy L. ;

Herbst, Ronald ;

Wang, Yue .

JOURNAL OF CLINICAL MEDICINE, 2016, 5 (12)

[8] Interleukin 6 signaling promotes anti-aquaporin 4 autoantibody production from plasmablasts in neuromyelitis optica [J].

Chihara, Norio ;

Aranami, Toshimasa ;

Sato, Wakiro ;

Miyazaki, Yusei ;

Miyake, Sachiko ;

Okamoto, Tomoko ;

Ogawa, Masafumi ;

Toda, Tatsushi ;

Yamamura, Takashi .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2011, 108 (09) :3701-3706

[9] Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2/3 trial [J].

Cree, Bruce A. C. ;

Bennett, Jeffrey L. ;

Kim, Ho Jin ;

Weinshenker, Brian G. ;

Pittock, Sean J. ;

Wingerchuk, Dean M. ;

Fujihara, Kazuo ;

Paul, Friedemann ;

Cutter, Gary R. ;

Marignier, Romain ;

Green, Ari J. ;

Aktas, Orhan ;

Hartung, Hans-Peter ;

Lublin, Fred D. ;

Drappa, Jorn ;

Barron, Gerard ;

Madani, Soraya ;

Ratchford, John N. ;

She, Dewei ;

Cimbora, Daniel ;

Katz, Eliezer ;

Shuey, Neil ;

Milanov, Ivan ;

Kaprelyan, Ara ;

Tarnev, Ivaylo ;

Haralanov, Lyubomir ;

Carruthers, Robert ;

Munoz, Mario ;

Quinones, Jairo ;

Vargas, Jose ;

Rodriguez, Jesus ;

Nytrova, Petra ;

Vachova, Marta ;

Mares, Jan ;

Haldre, Sulev ;

Gross-Paju, Katrin ;

Ziemssen, Tjalf ;

Zettl, Uwe Klaus ;

Klotz, Luisa ;

Bergh, Florian Then ;

Lau, Alexander ;

Dioszeghy, Peter ;

Satori, Maria ;

Vecsei, Laszlo ;

Achiron, Anat ;

Karni, Arnon ;

Vaknin-Dembinsky, Adi ;

Saida, Takahiko ;

Misu, Tatsuro ;

Baba, Masayuki .

LANCET, 2019, 394 (10206) :1352-1363

[10] Placebo-controlled study in neuromyelitis optica-Ethical and design considerations [J].

Cree, Bruce A. C. ;

Bennett, Jeffrey L. ;

Sheehan, Mark ;

Cohen, Jeffrey ;

Hartung, Hans-Peter ;

Aktas, Orhan ;

Kim, Ho Jin ;

Paul, Friedemann ;

Pittock, Sean ;

Weinshenker, Brian ;

Wingerchuk, Dean ;

Fujihara, Kazuo ;

Cutter, Gary ;

Patra, Kaushik ;

Flor, Armando ;

Barron, Gerard ;

Madani, Soraya ;

Ratchford, John N. ;

Katz, Eliezer .

MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (07) :862-872

← 1 2 3 4 →